Latest Articles

Publication Date
Ultrasound and single-port laparoscopic-guided microwave ablation of abdominal wall endometriosis lesions: A single-center observational study.

Raising the temperature of abdominal wall endometriosis lesions contributes to an effective ablation; however, providing sufficient protection to the surrounding tissues remains a challenge. In this study, we aimed to …

Published: Jan. 22, 2025, midnight
Percutaneous Cryoablation Therapy for Abdominal wall Endometriosis: a Systematic Review and Meta-analysis.

Abdominal wall endometriosis consists of endometrial tissue between the peritoneum and the abdominal wall. The established treatment involves amenorrheic drugs-not always successful and tolerated-or invasive surgery. In this scenario, minimally …

Published: Jan. 16, 2025, midnight
Safety evaluation of medroxyprogesterone acetate: a pharmacovigilance analysis using FDA adverse event reporting system data.

Medroxyprogesterone acetate (MPA), a synthetic progestogen, is extensively used for the treatment of various conditions, including contraception, irregular menstruation, functional uterine bleeding, and endometriosis. However, like all pharmaceutical agents, MPA …

Published: Dec. 11, 2024, midnight
Endometriosis and risk factors in pregnancy, labor and delivery: a case-control study.

It is a common thought that endometriosis and its related pain symptoms could improve during pregnancy. However, endometriosis was shown to affect the regular development of pregnancy and delivery outcomes. …

Published: Nov. 8, 2024, midnight
Self-Cross-Linked Hyaluronic Acid Gel for Adhesion Prophylaxis in Laparoscopic Deep Endometriosis Removal: Safety Report of a Prospective Pilot Study.

Background/Objectives: Surgical removal of deep endometriosis lesions is an established method of reducing patient symptoms, but it often results in iatrogenic adhesions that lead to further problems. This pilot study …

Published: Oct. 21, 2024, midnight
Postmarketing adverse events of tamoxifen in male and female patients with breast cancer.

Tamoxifen (TAM), a selective estrogen receptor (ER) modulator, has received approval for use in patients with breast cancer (BC) exhibiting positive ER expression. Given the widespread clinical use of TAM, …

Published: Sept. 21, 2024, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!